FVCM
BMY icon

F&V Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

F&V Capital Management’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.3M Buy
282,596
+6,095
+2% +$350K 3% 15
2026
Q1 		$16.8M Sell
276,501
-3,630
-1% -$212K 3.54% 10
2025
Q4 		$15.1M Buy
280,131
+106,916
+62% +$5.14M 3.21% 15
2025
Q3 		$7.81M Buy
173,215
+2,244
+1% +$105K 1.75% 25
2025
Q2 		$7.91M Buy
170,971
+250
+0.1% +$12.3K 2.02% 25
2025
Q1 		$10.4M Sell
170,721
-1,437
-0.8% -$83.8K 2.7% 20
2024
Q4 		$9.74M Buy
172,158
+1,600
+0.9% +$89.4K 2.56% 21
2024
Q3 		$8.82M Buy
170,558
+3,070
+2% +$144K 2.27% 24
2024
Q2 		$6.96M Buy
167,488
+9,180
+6% +$411K 2.03% 24
2024
Q1 		$8.59M Buy
158,308
+4,485
+3% +$228K 2.53% 21
2023
Q4 		$7.89M Buy
153,823
+220
+0.1% +$11.5K 2.53% 22
2023
Q3 		$8.91M Sell
153,603
-1,865
-1% -$114K 3.06% 14
2023
Q2 		$9.94M Sell
155,468
-1,630
-1% -$109K 3.21% 12
2023
Q1 		$10.9M Buy
157,098
+6,755
+4% +$476K 3.61% 12
2022
Q4 		$10.8M Buy
150,343
+250
+0.2% +$18.9K 3.6% 12
2022
Q3 		$10.7M Buy
150,093
+2,700
+2% +$196K 4.12% 6
2022
Q2 		$11.3M Buy
147,393
+5,285
+4% +$403K 4.04% 7
2022
Q1 		$10.4M Buy
142,108
+150
+0.1% +$10.1K 3.15% 13
2021
Q4 		$8.85M Buy
141,958
+12,405
+10% +$728K 2.97% 20
2021
Q3 		$7.67M Buy
129,553
+1,955
+2% +$129K 3.07% 19
2021
Q2 		$8.53M Buy
127,598
+47,173
+59% +$3.08M 3.13% 16
2021
Q1 		$5.08M Buy
80,425
+73,121
+1,001% +$4.55M 1.9% 27
2020
Q4 		$453K Buy
7,304
+3,975
+119% +$244K 0.2% 51
2020
Q3 		$201K Buy
+3,329
New +$200K 0.1% 58
2020
Q1 		– Sell
-3,429
Closed -$220K – 66
2019
Q4 		$220K Buy
+3,429
New +$196K 0.12% 56

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

F&V Capital Management's BMY Position: Q2 2026 in Review

F&V Capital Management increased its Bristol-Myers Squibb (BMY) stake by 2.2% in Q2 2026, buying an estimated $350K and bringing the position to 282,596 shares worth $16.3M. The position accounts for 3% of the portfolio, ranked #15.

F&V Capital Management first reported a position in BMY in Q4 2019 and has held it in 25 quarters since. The position peaked at $16.8M in Q1 2026. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • F&V Capital Management held 282,596 shares of Bristol-Myers Squibb worth $16.3M as of Q2 2026.
  • F&V Capital Management bought 6,095 Bristol-Myers Squibb shares in Q2 2026, an estimated $350K.
  • Bristol-Myers Squibb made up 3% of F&V Capital Management's portfolio in Q2 2026, its #15 holding.
  • F&V Capital Management first reported a position in Bristol-Myers Squibb in Q4 2019 and has held it in 25 quarters since.
  • F&V Capital Management's Bristol-Myers Squibb position peaked at $16.8M in Q1 2026.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on F&V Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.